Financial disclosures: A.S.C.: UCB (advisory board), Abbott (advisory board), Janssen (advisory board); the remaining authors have no relevant financial disclosures.
Varicella zoster virus infection in inflammatory bowel disease†
Article first published online: 20 MAR 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 12, pages 2392–2403, December 2012
How to Cite
Cullen, G., Baden, R. P. and Cheifetz, A. S. (2012), Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis, 18: 2392–2403. doi: 10.1002/ibd.22950
- Issue published online: 15 NOV 2012
- Article first published online: 20 MAR 2012
- Manuscript Accepted: 20 FEB 2012
- Manuscript Received: 15 FEB 2012
- viral infection;
- inflammatory bowel disease;
- Varicella zoster virus
The risk of viral infection is increased in immunosuppressed inflammatory bowel disease (IBD) patients. Varicella zoster virus (VZV) is of particular interest in IBD because of a number of reports of severe, disseminated, and occasionally fatal varicella infection in immunosuppressed IBD patients.
We reviewed publications describing VZV infection in IBD patients and combined these data with a review of the current literature relating to both primary and secondary varicella in IBD.
Twenty cases of primary varicella infection and 32 cases of herpes zoster infection have been reported in IBD. Additional cases are reported in clinical trials. The risk of VZV infection is increased with all immunosuppressants used in IBD, but corticosteroids and combination immunosuppression appear to be a particular risk.
Healthcare providers need to be aware of the various manifestations of primary and secondary VZV infection in immunosuppressed IBD patients. Patients should be screened for VZV immunity and vaccinated prior to commencing immunosuppression. (Inflamm Bowel Dis 2012;)